Advertisement


Eva M. Ciruelos, MD, PhD, on HER2-Positive and PAM50 Luminal Breast Cancer: Primary Results From the PATRICIA Trial

2024 ASCO Annual Meeting

Advertisement

Eva M. Ciruelos, MD, PhD, of Spain’s Hospital 12 de Octubre and the Instituto de Investigación Sanitaria Hospital 12 de Octubre, discusses phase II data showing that the combination of palbociclib, trastuzumab, and endocrine therapy improved progression-free survival in patients with previously treated PAM50 luminal A or B, HER2-positive advanced breast cancer, as compared with treatment of physicians’ choice (Abstract 1008).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
We presented the first primary results of the PATRICIA cohort C trial. This is an open level, phase two randomized trial that recruited HER2-positive advanced breast cancer patients who received an experimental combination consisted on palbociclib, trastuzumab and endocrine therapy versus treatment of physician choice with T-DM1 or the combination of trastuzumab chemotherapy or endocrine treatment. These patients were pre-treated patients, at least two prior lines of treatment, and all of them were selected based on the intrinsic subtyping. Just luminal A and luminal B tumors were included in this trial. Primary result was achieved and progression for survival was significantly improved with combination of palbociclib trastuzumab endocrine treatment over treatment of physician's choice, with a reduction in the risk of progression of about 48%, which is statistically significant. These results are unique as we try to select patients based on a new biomarker, which is intrinsic subtype, and offering this non-chemotherapy combination for these patients that harbored about 50% within the HER-positive HER2-positive disease. Regarding tolerability, no dose reductions were done differently from these two arms and no dose discontinuations were needed in the experimental arm. That is why our conclusions says that this is a new way to classify in patients within the HER2-positive disease. This is a non-chemo alternative for these patients that will translate, for sure, into quality of life. But still we should validate our results as our trial had some limitations due to a small sample size, so maybe new prospective randomized designs will be needed to confirm our [inaudible 00:02:21] results.

Related Videos

Skin Cancer

Axel Hauschild, MD, on Melanoma: Findings From the PIVOTAL Trial of Daromun vs Surgery

Axel Hauschild, MD, of Germany’s University of Kiel and University Hospital Schleswig-Holstein, discusses phase III study results on neoadjuvant intralesional daromun vs immediate surgery for patients with fully resectable, locally advanced melanoma (Abstract LBA9501).

Leukemia
Lymphoma

William G. Wierda, MD, PhD, on CLL/SLL: Updated Findings on Ibrutinib and Venetoclax

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses up to 5.5 years of follow-up data from the phase II CAPTIVATE study, showing that in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), fixed duration ibrutinib plus venetoclax continues to provide clinically meaningful progression-free disease in those with high-risk genomic features as well as in the overall population (Abstract 7009).

Leukemia
Lymphoma

Muhit Özcan, MD, on CLL/SLL: Report on a Still-Recruiting International Study of Nemtabrutinib, Venetoclax, and Rituximab

Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses the ongoing phase III BELLWAVE-010 study of nemtabrutinib plus venetoclax vs venetoclax plus rituximab in previously treated patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) (Abstract TPS7089).  

Multiple Myeloma

Thierry Facon, MD, on Multiple Myeloma: Results From the IMROZ Study on Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone

Thierry Facon, MD, of the University of Lille and Lille University Hospital, discusses phase III findings showing for the first time that isatuximab, an anti-CD38 monoclonal antibody, when given with the standard of care (bortezomib, lenalidomide, dexamethasone, or VRd) to patients with newly diagnosed multiple myeloma who are transplant-ineligible, may reduce the risk of disease progression or death by 40.4% vs VRd alone (Abstract 7500).

Breast Cancer

Lisa A. Carey, MD, and Kevin Kalinsky, MD, on Advanced Breast Cancer: New Data on Abemaciclib and Fulvestrant From the postMONARCH Trial

Lisa A. Carey, MD, of University of North Carolina, Chapel Hill and UNC Lineberger Comprehensive Cancer Center, and Kevin Kalinsky, MD, of the Winship Cancer Institute of Emory University, discuss the first phase III findings showing a benefit of continued CDK4/6 inhibition with abemaciclib plus fulvestrant, following disease progression in patients with hormone receptor–positive, HER2-negative advanced breast cancer (LBA1001).

Advertisement

Advertisement




Advertisement